Introduction
In this study we focused on individuals showing an atypical pattern in their macular pigment, specifically those with a “central dip”, a deficiency in pigment right at the centre of the macula. This investigation followed our earlier research that showed positive carotenoid responses overall but uncovered this unique subgroup with a nutrient gap.
Why was the research undertaken?
We found that about 12% of the population had this central dip in the centre of their macular pigment, and previous trials using lutein alone did not fix it. Because meso-zeaxanthin is the main carotenoid found in the central macula, we hypothesized that supplementation including meso-zeaxanthin could rebuild the central pigment in these individuals.
How was the study conducted?
From a large Irish population, we identified people with central dips and enrolled them into a head-to-head clinical trial. Participants were randomly assigned to three groups: lutein-only supplementation, meso-zeaxanthin-only supplementation, or a combination of lutein, zeaxanthin, and meso-zeaxanthin. The aim was to find out which supplement could effectively restore central macular pigment.
What were the results?
We demonstrated that only the formulations containing meso-zeaxanthin succeeded in rebuilding the central macular pigment. Supplements without meso-zeaxanthin, containing just lutein and zeaxanthin, failed to correct the central dip. This revealed a specific nutrient deficiency in meso-zeaxanthin for this subgroup, with important implications for those at risk of or suffering from macular degeneration.
What is the societal benefit?
This research was a significant scientific breakthrough, identifying a previously unrecognized nutrient deficiency linked to macular health. It informed clinical practice by showing that meso-zeaxanthin is essential for restoring central macular pigment effectively. The findings laid the groundwork for larger studies and improved strategies to prevent and treat macular degeneration.
